Dataset Information

Functional Heterogeneity Analysis of Mesenchymal Stem Cell Lines and their Therapeutic Potential in the K18-hACE2 Mouse Model of SARS-CoV-2 Infection

ABSTRACT: Despite many years of investigation into mesenchymal stem cells (MSCs) and their potential for treating inflammatory conditions such as COVID-19, clinical outcomes remain variable due to factors like donor variability, different tissue sources, and diversity within MSC populations. Variations in MSCs' secretory and proliferation profiles, and their proteomic and transcriptional characteristics significantly influence their therapeutic potency, highlighting the need for standardized and enhanced characterization methods to better predict their efficacy. This study aimed to evaluate the biological characteristics and therapeutic efficacy of MSCs from different tissue origins, selecting the most promising line for further validation in a K18-hACE2 mouse model of SARS-CoV-2 infection.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Mesenchymal Stem Cell, Mesenchymal Stem Cell Of Umbilical Cord, Mesenchymal Stem Cell Of The Bone Marrow, Bone Marrow, Dental Pulp Stem Cell

SUBMITTER: Gisele Rocha

LAB HEAD: Bruno Solano de Freitas Souza

PROVIDER: PXD051984 | Pride | 2025-05-07

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20210625_32421_Dalila_RSM_1.RAW	Raw
	20210625_32421_Dalila_RSM_2.RAW	Raw
	20210625_32421_Dalila_RSM_3.RAW	Raw
	20210625_32521_Dalila_LN_1.RAW	Raw
	20210625_32521_Dalila_LN_2.RAW	Raw

Items per page:

1 - 5 of 37

Publications

Functional heterogeneity of mesenchymal stem cells and their therapeutic potential in the K18-hACE2 mouse model of SARS-CoV-2 infection.

da Silva Kátia Nunes KN Marim Fernanda Martins FM Rocha Gisele Vieira GV Costa-Ferro Zaquer Suzana Munhoz ZSM França Luciana Souza de Aragão LSA Nonaka Carolina Kymie Vasques CKV Paredes Bruno Diaz BD Rossi Erik Aranha EA Loiola Erick Correia EC Adanho Corynne Stephanie Ahouefa CSA Cunha Rachel Santana RS Silva Mayck Medeiros Amaral da MMAD Cruz Fernanda Ferreira FF Costa Vivian Vasconcelos VV Zanette Dalila Lucíola DL Rocha Clarissa Araújo Gurgel CAG Aguiar Renato Santana RS Rocco Patricia Rieken Macedo PRM Souza Bruno Solano de Freitas BSF

Stem cell research & therapy 20250123 1

<h4>Background</h4>Despite many years of investigation into mesenchymal stem cells (MSCs) and their potential for treating inflammatory conditions such as COVID-19, clinical outcomes remain variable due to factors like donor variability, different tissue sources, and diversity within MSC populations. Variations in MSCs' secretory and proliferation profiles, and their proteomic and transcriptional characteristics significantly influence their therapeutic potency, highlighting the need for enhance ...[more]

PMID: 39849557

Similar Datasets

Project description:Rapid emergence of antigenic distinct SARS-CoV-2 variants implies a greater risk of reinfection as viruses can escape neutralizing antibodies induced by vaccination or previous viral exposure. Disease severity during COVID-19 depends on many variables such as age-related comorbidities, host immune status and genetic variation. The host immune response during infection with SARS-CoV-2 may contribute to disease severity, which can range from asymptomatic to severe with fatal outcome. Furthermore, the extent of host immune response activation may rely on underlying genetic predisposition for disease or protection. To address these questions, we performed immune profiling studies in mice with different genetic backgrounds - transgenic K18-hACE2 and wild-type 129S1 mice – subjected to reinfection with the severe disease-causing SARS-CoV-2 B.1.351 variant, 30 days after experimental milder BA.1 infection. BA.1 preinfection conferred protection against B.1.351-induced morbidity in K18-hACE2 mice but aggravated disease in 129S1 mice. We found that he cytokine/chemokine profile in B.1.351 re-infected 129S1mice is similar to that during severe SARS-CoV-2 infection in humans and is characterized by a much higher level of IL-10, IL-1β, IL-18 and IFN-γ , whereas in B.1.351 re-infected K18-hACE2 mice, the cytokine profile echoes the signature of naïve mice undergoing viral infection for the first time. Interestingly, the enhanced pathology observed in 129S1 mice upon reinfection cannot be attributed to a less efficient induction of adaptive immune responses to the initial BA.1 infection, as both K18-hACE2 and 129S1 mice exhibited similar B and T cell responses at 30 DPI against BA.1, with similar anti-BA.1 or B.1.351 spike-specific ELISA binding titers, levels of germinal center B-cells, and SARS-CoV-2-Spike specific tissue-resident T-cells. Long-term effects of BA.1 infection are associated with differential transcriptional changes in bronchoalveolar lavage-derived CD11c+ immune cells from K18-hACE2 and 129S1, with K18-hACE2 CD11c+ cells showing a strong antiviral defense gene expression profile whereas 129S1 CD11c+ cells showed a more pro-inflammatory response. In conclusion, initial infection with BA.1 induces cross-reactive adaptive immune responses in both K18-hACE2 and 129S1 mice, however the different disease outcome of reinfection seems to be driven by differential responses of CD11c+ cells in the alveolar space.